📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 16:44
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
MKPL Q1 FY27 Net Profit Drops 60.7% YoY to ₹1.38 Cr Amid Margin Contraction
M K Proteins Limited (MKPL) reported flat revenue growth for Q1 FY27 at ₹115.16 Cr compared to ₹114.95 Cr in Q1 FY26. However, Net Profit declined sharply by 60.7% YoY to ₹1.38 Cr, down from ₹3.51 Cr, as total expenses consumed a larger portion of revenue. Sequentially, revenue fell 21% from ₹145.94 Cr in Q4 FY26, though profit showed a marginal recovery from ₹1.14 Cr. Additionally, Independent Director Ms. Laxmi Mandal resigned effective August 12, 2026.
Confidence: HIGH
What changedMKPL released its Q1 FY27 results showing a sharp YoY profit decline despite stable revenue, alongside the resignation of an Independent Director.
Why it mattersThe results highlight the company's vulnerability to margin pressure in a fragmented industry where it lacks pricing power, despite having a locational advantage in Gujarat.
Revenue (Q1 FY27): ₹115.16 CrNet Profit (Q1 FY27): ₹1.38 CrYoY Profit Growth: -60.7%QoQ Revenue Growth: -21.1%PBT Margin (Q1 FY27): 1.6%
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the significant YoY profit decline and margin contraction.
📈 Long termThe long-term outlook depends on the company's ability to scale its mechanized refinery operations and manage raw material procurement costs effectively in a highly competitive market.
⚠ Risk flags
- Significant margin contraction
- High raw material cost sensitivity
- Independent Director resignation
Key Highlights
Revenue from operations remained stagnant at ₹115.16 Cr vs ₹114.95 Cr YoY.
Net Profit fell significantly to ₹1.38 Cr from ₹3.51 Cr in the year-ago period.
Total expenses rose to 98.4% of revenue in Q1 FY27, up from 95.9% in Q1 FY26.
Earnings Per Share (EPS) declined to ₹0.04 from ₹0.09 YoY.
Independent Director Ms. Laxmi Mandal resigned from the board on August 12, 2026.
👀 What to Watch
Investors should monitor the company's operating margins in upcoming quarters to see if the current compression is a one-off or a structural trend due to raw material price volatility. The high sensitivity to input costs and low pricing power remain key educational points for this micro-cap stock.
MKPL Approves FY26 Audited Financial Results and Re-appoints Auditors
M K Proteins Limited (MKPL) has approved its audited standalone financial results for the quarter and year ended March 31, 2026. The statutory auditors, Subhash Sajal & Associates, have issued an unmodified opinion, signifying the reliability of the financial statements. To maintain governance continuity, the board re-appointed M/s. K. K. Sinha & Associates as Cost Auditors and M/s. Jayant Bansal & Co. as Internal Auditors for the 2026-27 fiscal year. Additionally, the company confirmed that there are no outstanding defaults on loans or debt securities as of the end of the financial year.
Key Highlights
Approved audited standalone financial results for the quarter and year ended March 31, 2026
Statutory auditors issued a report with an unmodified opinion on the financial results
Re-appointed M/s. K. K. Sinha & Associates as Cost Auditors for FY 2026-27
Re-appointed M/s. Jayant Bansal & Co. as Internal Auditors for FY 2026-27
Reported zero outstanding defaults on loans and debt securities as of March 31, 2026
👀 What to Watch
Investors should review the detailed financial performance metrics in the full report to assess operational efficiency. The unmodified audit opinion and continuity of auditors are positive indicators of stable corporate governance.
MKPL Approves FY26 Audited Results; Re-appoints Cost and Internal Auditors
M K Proteins Limited (MKPL) has approved its audited standalone financial results for the quarter and full year ended March 31, 2026. The statutory auditors, Subhash Sajal & Associates, issued an unmodified opinion, confirming the reliability of the financial statements. The board also re-appointed M/s. K. K. Sinha & Associates as Cost Auditors and M/s. Jayant Bansal & Co. as Internal Auditors for the 2026-27 fiscal year. Additionally, the company reported zero defaults on loans and debt securities as of the year-end.
Key Highlights
Approval of audited standalone financial results for the quarter and year ended March 31, 2026.
Statutory auditors issued a clean (unmodified) opinion on the company's financial health.
Re-appointment of Cost and Internal Auditors for the financial year 2026-27 to ensure continued compliance.
Confirmed no outstanding defaults on loans or debt securities as of March 31, 2026.
👀 What to Watch
Investors should review the specific revenue and profit figures once the full XBRL data is available to assess growth trends. The clean audit report is a positive indicator of financial transparency.
MKPL Q3 FY26 Revenue Jumps 127% YoY to ₹89.56 Cr; Net Profit Rises to ₹1.43 Cr
M K Proteins Limited reported a substantial 127% YoY increase in revenue for Q3 FY26, reaching ₹89.56 crore compared to ₹39.48 crore in the previous year. However, net profit grew by only 4% YoY to ₹1.43 crore, indicating significant margin pressure as expenses rose sharply. For the nine-month period ending December 2025, revenue surged 81.5% to ₹236.93 crore, while net profit saw a marginal increase to ₹5.69 crore. The sharp rise in raw material costs and stock-in-trade purchases impacted the overall profitability despite the robust top-line performance.
Key Highlights
Revenue from operations grew 126.8% YoY to ₹89.56 crore in Q3 FY26.
Net profit for the quarter increased slightly by 4% YoY to ₹1.43 crore.
9-month revenue reached ₹236.93 crore, up from ₹130.50 crore in the previous year.
Quarterly EPS improved to ₹0.04 compared to ₹0.02 in the previous quarter.
Total expenditure for the quarter rose to ₹87.61 crore, driven by a surge in material consumption and stock purchases.
👀 What to Watch
While the top-line growth is exceptional, the stagnant bottom line suggests rising input costs are significantly impacting margins. Investors should monitor the company's ability to pass on costs to maintain profitability before making aggressive entries.
M K Proteins Q3 FY26 Revenue Surges 126% YoY to Rs 89.55 Crore
M K Proteins Limited (MKPL) reported a massive 126% year-on-year increase in revenue from operations for Q3 FY26, reaching Rs 8,955.83 lacs. However, net profit saw a more modest growth of 4%, rising to Rs 143.08 lacs from Rs 137.52 lacs in the previous year's corresponding quarter. For the nine-month period ended December 2025, the company achieved a revenue of Rs 23,693.46 lacs, nearly doubling its performance compared to the same period last year. The results indicate strong top-line momentum but suggest significant pressure on operating margins due to increased material costs.
Key Highlights
Revenue from operations grew 126.8% YoY to Rs 8,955.83 lacs in Q3 FY26.
Net profit for the quarter stood at Rs 143.08 lacs, up from Rs 137.52 lacs in Q3 FY25.
Nine-month revenue for FY26 reached Rs 23,693.46 lacs compared to Rs 13,050.19 lacs in 9M FY25.
Cost of materials consumed rose sharply to Rs 8,569.66 lacs in Q3 FY26 from Rs 2,003.69 lacs in Q3 FY25.
Earnings Per Share (EPS) for the quarter remained stable at Rs 0.04.
👀 What to Watch
Investors should note the exceptional top-line growth but remain cautious about the thinning profit margins as raw material costs have scaled significantly. Monitor if the company can improve its operational efficiency to translate high sales into higher bottom-line growth in future quarters.
